Respiratory Syncytial Virus Trials Focus on Children

Vol. 10, No. 4
December, 2000

  • Winthrop Ranked #1 in Metropolitan Region for Open-Heart Surgery

  • Telemetry Monitoring Units Safeguard Cardiac Patients

  • Cardiac Rehabilitation Program Certified

  • Uterine Artery Embolization:
    A Non-Surgical Approach to Fibroid Tumors

  • Osteoporosis Studies Recruit Women

  • Senator Balboni Sponsors Grant for Neonatal Transport System

  • Re-Opening of Expanded Pulmonary Rehabilitation Unit

  • Respiratory Syncytial Virus Trials Focus on Children

  • Combating Tickborne Infectious Diseases

  • Warding off the Flu

  • Arabian Nights Gala Benefits Hospital

  • Changes to Winthrop�s Board of Directors

  • New Members Elected to Winthrop�s Board of Directors

  • Winthrop Directors Cut Ribbon at New Hospital Entrance

  • Senior Volunteer Awards Luncheon
    In appreciation of our devoted volunteers

  • New Name For The Long Island Poison Control Center

  • Winthrop Hosts Child Health Plus Open Enrollment


  • Copyright

    Back to Publications

  • Leonard R. Krilov, MD, Chief, Division of Pediatric Infectious Diseases at Winthrop
    Respiratory Syncytial Virus (RSV) may not be a household word, but it is the leading cause of lower respiratory tract infection in babies and very young children. RSV infection ranges from mild cold symptoms to life-threatening lung disease. Children born prematurely, before the 35th week of gestation, are considered the most vulnerable.

    Currently, RSV causes more than 100,000 pediatric hospitalizations per year in the United States, usually during the first two years of a child�s life. Most children who are hospitalized with RSV recover completely. �However, children born prematurely, or with underlying chronic or congenital lung disease, are at a greater risk of having RSV escalate into a more serious disease,� explained Leonard R. Krilov, MD, an expert in RSV, who is Chief, Division of Pediatric Infectious Diseases at Winthrop � part of Winthrop�s Institute for Family Care.

    �Efforts toward the prevention of RSV disease are aimed at premature infants and those with congenital or acquired lung disease. Pediatricians are equipped to administer the preventive immunization, Synagis™, during the child�s first two years of life,� said Dr. Krilov. �The inoculations are given monthly, beginning in October or November, to provide protection during January and February, the months of the greatest incidences of RSV.�

    In l998, Synagis™ was FDA-approved for premature babies and for newborns with congenital lung problems. Synagis™ is a monoclonal antibody that provides extra antibodies to combat RSV, which translates into greater protection. Full-term, healthy babies rarely need Synagis™, which requires five to six visits to the pediatrician for inoculations, during each of the one or two years during which it is administered.

    Dr. Krilov is Principal Investigator of a clinical trial of the efficacy of Synagis™ when prescribed for children with congenital heart disease. The purpose of the trial is to win FDA approval of the drug for this category of patients, if it proves effective. Now in its third year, the trial�s other investigators include Winthrop attending physicians Carlos Montoya, MD, Chief, Pediatric Cardiology, Donna J. Better, MD, Faculty Attending, Pediatric Cardiology, and Paul Lee, MD, Faculty Attending, Pediatric Infectious Disease.

    Dr. Krilov has administered the medication to babies in the high risk group, with congenital heart defects, who are just a few days old.

    Medically appropriate children who participate are availed of treatment with promising new pharmaceuticals, and are closely monitored by specialists, at no cost. If the drug works for the baby, the baby�s improved health is an obvious and immediate benefit. Other benefits include learning more about the baby�s diagnosis and congenital condition. Participants have the satisfaction of helping not only themselves, but future generations of patients. They have also helped to add to overall medical knowledge.

    �The real purpose of clinical trials is to learn how new pharmaceuticals can help children. Participation is in the best interests of the children. Although adult trials are very efficacious, and we learn a lot, the applications are usually delayed in reaching children,� said Dr. Krilov. �That is partly because the medication must be reformulated as a liquid, in the correct dosage, for children. This takes time.�

    Additionally, Dr. Krilov and faculty attending pediatric infectious disease specialists provide a full array of consultative services. As clinicians, Dr. Krilov and his colleague, Dr. Paul Lee, provide care to newly-adopted international babies. Dr. Krilov is experienced in the established protocols for performing health assessments of the foreign-born babies, who may have been exposed to forms of infection not usually seen in the United States.

    For further information about the Division of Pediatric Infectious Disease, or to have your child screened for participation in the Synagis™ clinical trial, call Dr. Krilov at (516) 663-9400.

    [ Home | Search | Contact | Directions | Privacy Notice ]

    Winthrop-University Hospital | 259 First Street | Mineola NY 11501 | 516-663-0333

    This site provides information as a resource. It is not a substitute for professional medical advice.
    Always consult a physician or healthcare provider for treatment and guidance toward good health.
    Copyright © 2008 Winthrop-University Hospital. All rights reserved. Long Island Web Design